POMP combination chemotherapy of adult acute leukemia

Victorio Rodriguez; Jacqueline S. Hart; Emil J. Freireich; Gerald P. Bodey; Kenneth B. McCredie; John P. Whitecar; Charles A. Coltman

doi:10.1002/1097-0142(197307)32:1<69::AID-CNCR2820320109>3.0.CO;2-0

POMP combination chemotherapy of adult acute leukemia

Victorio Rodriguez, Jacqueline S. Hart, Emil J. Freireich, Gerald P. Bodey, Kenneth B. McCredie, John P. Whitecar, Charles A. Coltman

Graduate School of Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

59 Scopus citations

Abstract

Eighty‐nine adults with acute leukemia (AML and ALL) were treated with a combination of 6‐mercaptopurine (Purinethol), vincristine (Oncovin), methotrexate, and prednisone [POMP] for remission induction and maintenance. The overall response rate was 53% and the complete remission rate 40%. The median duration of maintained complete remission was 24 weeks. The median survival time for all patients was 7 months. For the patients who responded, the median survival time was 13 months. Age and previous therapy were major factors influencing the response of the patients in this study. Side effects other than myelosuppression resulted in liver function abnormalities, minor gastrointestinal intolerance, and paresthesias. POMP chemotherapy is effective remission induction and maintenance therapy for adults with acute leukemia under the age of 50 and who have not had prior chemotherapy.

Original language	English (US)
Pages (from-to)	69-75
Number of pages	7
Journal	Cancer
Volume	32
Issue number	1
DOIs	https://doi.org/10.1002/1097-0142(197307)32:1<69::AID-CNCR2820320109>3.0.CO;2-0
State	Published - Jul 1973

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(197307)32:1<69::AID-CNCR2820320109>3.0.CO;2-0

Cite this

@article{5ffbe5750c104911abf5358f30031d12,

title = "POMP combination chemotherapy of adult acute leukemia",

abstract = "Eighty‐nine adults with acute leukemia (AML and ALL) were treated with a combination of 6‐mercaptopurine (Purinethol), vincristine (Oncovin), methotrexate, and prednisone [POMP] for remission induction and maintenance. The overall response rate was 53% and the complete remission rate 40%. The median duration of maintained complete remission was 24 weeks. The median survival time for all patients was 7 months. For the patients who responded, the median survival time was 13 months. Age and previous therapy were major factors influencing the response of the patients in this study. Side effects other than myelosuppression resulted in liver function abnormalities, minor gastrointestinal intolerance, and paresthesias. POMP chemotherapy is effective remission induction and maintenance therapy for adults with acute leukemia under the age of 50 and who have not had prior chemotherapy.",

author = "Victorio Rodriguez and Hart, {Jacqueline S.} and Freireich, {Emil J.} and Bodey, {Gerald P.} and McCredie, {Kenneth B.} and Whitecar, {John P.} and Coltman, {Charles A.}",

year = "1973",

month = jul,

doi = "10.1002/1097-0142(197307)32:1<69::AID-CNCR2820320109>3.0.CO;2-0",

language = "English (US)",

volume = "32",

pages = "69--75",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - POMP combination chemotherapy of adult acute leukemia

AU - Rodriguez, Victorio

AU - Hart, Jacqueline S.

AU - Freireich, Emil J.

AU - Bodey, Gerald P.

AU - McCredie, Kenneth B.

AU - Whitecar, John P.

AU - Coltman, Charles A.

PY - 1973/7

Y1 - 1973/7

N2 - Eighty‐nine adults with acute leukemia (AML and ALL) were treated with a combination of 6‐mercaptopurine (Purinethol), vincristine (Oncovin), methotrexate, and prednisone [POMP] for remission induction and maintenance. The overall response rate was 53% and the complete remission rate 40%. The median duration of maintained complete remission was 24 weeks. The median survival time for all patients was 7 months. For the patients who responded, the median survival time was 13 months. Age and previous therapy were major factors influencing the response of the patients in this study. Side effects other than myelosuppression resulted in liver function abnormalities, minor gastrointestinal intolerance, and paresthesias. POMP chemotherapy is effective remission induction and maintenance therapy for adults with acute leukemia under the age of 50 and who have not had prior chemotherapy.

AB - Eighty‐nine adults with acute leukemia (AML and ALL) were treated with a combination of 6‐mercaptopurine (Purinethol), vincristine (Oncovin), methotrexate, and prednisone [POMP] for remission induction and maintenance. The overall response rate was 53% and the complete remission rate 40%. The median duration of maintained complete remission was 24 weeks. The median survival time for all patients was 7 months. For the patients who responded, the median survival time was 13 months. Age and previous therapy were major factors influencing the response of the patients in this study. Side effects other than myelosuppression resulted in liver function abnormalities, minor gastrointestinal intolerance, and paresthesias. POMP chemotherapy is effective remission induction and maintenance therapy for adults with acute leukemia under the age of 50 and who have not had prior chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0015643568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015643568&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197307)32:1<69::AID-CNCR2820320109>3.0.CO;2-0

DO - 10.1002/1097-0142(197307)32:1<69::AID-CNCR2820320109>3.0.CO;2-0

M3 - Article

C2 - 4515259

AN - SCOPUS:0015643568

SN - 0008-543X

VL - 32

SP - 69

EP - 75

JO - Cancer

JF - Cancer

IS - 1

ER -

POMP combination chemotherapy of adult acute leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this